title: Propofol treatment in adult refractory status epilepticus. Mortality risk and outcome.
abstract: OBJECTIVE
  To retrospectively study effect and safety of propofol treatment in adult refractory generalised tonic clonic status epilepticus.
  
  
  BACKGROUND
  Therapy refractory status epilepticus (RSE) is defined as a status that does not respond to 1st or 2nd line of treatment. Different anaesthetics are used to treat RSE, but no definite recommendations or priority has been scientifically established.
  
  
  METHODS
  Propofol has been the preferred agent for treating RSE at our intensive care unit since 2001. We present treatment mode, effect and outcome in 18 patients with 27 consecutive cases of RSE treated 2001-2010. Fifteen patients had 1 episode, and 3 patients had 2, 3 and 7 episodes, respectively. Mortality risk for each case of RSE was estimated using the Simplified Acute Physiology (SAPS) II score.
  
  
  RESULTS
  Probable trigger factors were identified for 22 of the 27 RSE episodes. In 16/27 episodes seizures lasted more than 2h before anaesthesia was induced. A mean total dose of 7885.1mg was given for a mean duration of 34.4h. Break through seizures occurred in 8 of the patients and in 2 episodes of RSE in one patient, i.e. 9/27 episodes of RSE. Propofol was changed to another anaesthetic agent in 2 episodes. Complications occurred in 17 of the RSE episodes, the most frequent was pneumonia (9/27). One patient had complications that could be related to a propofol infusion syndrome (PRIS). In 8 of 18 patients and 14/27 RSE episodes no sequelae occurred. Seven episodes were associated with mild and 4 with severe sequelae and 2 of the patients died. We found a trend only for SAPS II score being higher in patients with more severe sequelae.
  
  
  CONCLUSIONS
  Our data support propofol as an effective anaesthetic for treating RSE. Close clinical observation for possible PRIS is warranted if propofol is given for more than 48h.
authors.affiliation: Department of Neurology, Haukeland University Hospital, Bergen, Norway. kjersti.nesheim.power@helse-bergen.no
authors.forename: Kjersti Nesheim
authors.initials: KN
authors.lastname: Power
authors.forename: Hans
authors.initials: H
authors.lastname: Flaatten
authors.forename: Nils Erik
authors.initials: NE
authors.lastname: Gilhus
authors.forename: Bernt A
authors.initials: BA
authors.lastname: Engelsen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use*; D038801:International Classification of Diseases; D008297:Male; D008875:Middle Aged; D010808:Physical Examination; D015742:Propofol / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013226:Status Epilepticus / Q000188:drug therapy* / Q000401:mortality*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006993:Hypnotics and Sedatives; D015742:Propofol